Autopsy report · NCT04278963

Yinhu Qingwen Decoction for the Treatment of Mild / Common CoVID-19

“There were no eligible patients in the paticipated centers.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 8 months before it started.
• Suspended: paused, and may or may not restart.
• 300 participants planned (an estimate, not an actual count).

Vital statistics

Status

Suspended

Phase

Phase 2, Phase 3

Sponsor

China Academy of Chinese Medical Sciences

Sponsor type

University, hospital or other

Conditions

CoVID-19; Chinese Medicine

Interventions

YinHu QingWen Decoction; YinHu QingWen Decoction(low dose); Chinese medicine treatment; standard western medicine treatment

Participants

300 (planned, not actual)

Sites

3

Countries

China

Trials that died the same way

• Recombinant Human Interleukin-11 Combination Low-dose Rituximab in Immune Thrombocytopenia
  “No eligible patients were enrolled.” (84% match in meaning)
• Use of the INAMED LAPBAND System to Reduce BMI's in Obese Renal Failure Patients
  “No patients were enrolled.” (83% match in meaning)
• Energy Expenditure and Gastric Bypass Surgery
  “no patients enrolled.” (81% match in meaning)
• Recombinant Human Thrombopoietin (rhTPO) Combining Rituximab Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)
  “No eligible patient was enrolled.” (80% match in meaning)
• Safety and Efficacy of Cryoablation Combined With Radiation Therapy for the Palliation of Painful Bone Metastases
  “No patients were treated due to enrollment challenges.” (78% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.